Kane Biotech Inc.
KNBIF
$0.02
$0.00-8.08%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -80.38% | -72.63% | 141.30% | 1,344.70% | 1,281.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -80.38% | -72.63% | 141.30% | 1,344.70% | 1,281.40% |
| Cost of Revenue | -65.94% | -36.66% | 354.50% | 3,358.41% | 2,919.86% |
| Gross Profit | -100.25% | -109.52% | 2.44% | 612.46% | 690.86% |
| SG&A Expenses | -37.60% | -52.49% | -30.74% | 21.12% | 26.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.23% | -47.27% | -13.10% | 55.82% | 63.76% |
| Operating Income | 31.78% | 35.02% | 38.80% | 2.44% | -9.64% |
| Income Before Tax | 38.44% | 35.92% | 41.33% | 17.84% | 3.25% |
| Income Tax Expenses | 91.72% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.05% | 61.82% | 64.48% | 43.40% | 30.96% |
| Earnings from Discontinued Operations | -- | -112.16% | -111.70% | 3,258.52% | 2,042.75% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -143.26% | -156.72% | -166.27% | 220.19% | 219.94% |
| EBIT | 31.78% | 35.02% | 38.80% | 2.44% | -9.64% |
| EBITDA | 33.08% | 36.98% | 39.39% | 1.30% | -10.66% |
| EPS Basic | -133.02% | -151.29% | -168.08% | 215.33% | 210.96% |
| Normalized Basic EPS | 55.19% | 47.06% | 46.39% | 23.16% | 6.67% |
| EPS Diluted | -157.47% | -172.09% | -213.13% | 172.97% | 168.00% |
| Normalized Diluted EPS | 53.74% | 45.40% | 44.92% | 25.86% | 9.26% |
| Average Basic Shares Outstanding | 62.67% | 40.26% | 7.38% | 2.97% | 0.81% |
| Average Diluted Shares Outstanding | 58.17% | 36.99% | 5.54% | 3.71% | 1.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |